Effect of Short-Term Oral Valproic Acid on Vision and Visual Field in Retinitis Pigmentosa
The aim of this study was to evaluate the effect of short-term oral valproic acid (VPA) on the vision and visual fields of patients with retinitis pigmentosa (RP).
In this prospective, nonrandomized trial, 10 patients (20 eyes) with established RP were treated with oral VPA 500 mg/day for 3 months. Visual acuity was monitored using the Snellen chart and values were converted into Early Treatment Diabetic Retinopathy Study chart and logarithm of the minimum angle of resolution (logMAR) equivalents. Visual field changes were evaluated using the Humphrey visual field analyzer (30-2 SITA standard test protocol).
Mean visual acuity was significantly improved from a pretreatment value of 20/72 (logMAR 0.560 ± 0.488) to 20/65 (logMAR 0.513 ± 0.422) after 3 months of treatment (P = 0.006). Vision improved by at least one line or more than one line in 10 eyes, and remained stable in the other 10 eyes. Visual field improvement was noted in nine eyes (P < 0.05, χ2 test), nine showing no significant field change and in two visual fields could not be recorded due to poor vision.
Short-term (3-month) treatment with VPA improves the vision and visual field of patients with RP.
- Clemson, CM, Tzekov, R, Krebs, M (2011) Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol 95: pp. 89-93 CrossRef
- Schooneveld, MJ, Born, LI, Genderen, M (2011) The conclusions of Clemson et al. concerning valproic acid are premature. Br J Ophthalmol 95: pp. 153 CrossRef
- Sandberg, MA, Rosner, B, Weigel-DiFranco, C (2011) Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br J Ophthalmol 95: pp. 744 CrossRef
- Holladay, JT (1997) Proper method of calculating average visual acuity. J Refract Surg 13: pp. 388-391
- Heijl, A, Lindgren, G, Olsson, J, Asman, P (1989) Visual field interpretation with empiric probability maps. Arch Ophthalmol 107: pp. 204-208 CrossRef
- Leske, MC, Heijl, A, Hyman, L (1999) Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology 106: pp. 2144-2153 CrossRef
- Heijl, A, Leske, MC, Bengtsson, B (2003) Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 81: pp. 286-293 CrossRef
- Merin, S, Obolensky, A, Farber, MD (2008) A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther 24: pp. 80-86 CrossRef
- Berson, EL, Rosner, B, Weigel-DiFranco, C (2002) Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci 43: pp. 3027-3036
- Noorwez, SM, Ostrov, DA, McDowell, JH (2008) A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci 49: pp. 3224-3230 CrossRef
- Göttlicher, M, Minucci, S, Zhu, P (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: pp. 6969-6978 CrossRef
- Massof, R, Dagnelie, G, Benzschawel, T (1990) First order dynamics of visual field loss in retinitis pigmentosa. Clin Vision Sci 5: pp. 1-26
- Effect of Short-Term Oral Valproic Acid on Vision and Visual Field in Retinitis Pigmentosa
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Ophthalmology and Therapy
- Online Date
- November 2012
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- Retinitis pigmentosa
- Valproic acid
- Visual field
- Visual improvement